Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ALS ( (AU:ALQ) ) has issued an update.
ALS Limited announced a change in the director’s interest, with Malcolm Deane acquiring 146,884 Performance Rights under the company’s 2025 Long-Term Incentive Plan, following shareholder approval at the 2025 AGM. This acquisition increases Deane’s total holdings and reflects ALS’s commitment to aligning executive interests with company performance, potentially impacting stakeholder confidence and the company’s market positioning.
The most recent analyst rating on (AU:ALQ) stock is a Buy with a A$23.50 price target. To see the full list of analyst forecasts on ALS stock, see the AU:ALQ Stock Forecast page.
More about ALS
ALS Limited operates in the testing, inspection, and certification industry, providing a range of services to various sectors including environmental, food, pharmaceutical, and industrial markets. The company focuses on delivering high-quality analytical testing and laboratory services to ensure safety and compliance across multiple industries.
Average Trading Volume: 1,316,957
Technical Sentiment Signal: Buy
Current Market Cap: A$11.1B
For a thorough assessment of ALQ stock, go to TipRanks’ Stock Analysis page.